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Evaluating interactions between  
hyperglycemia and clotting factors in  
patients suffering with SARS-CoV-2 infection
ABSTRACT
Background. With coronavirus disease-19 (COVID-19), 
patients with diabetes mellitus are dealing with two 
pandemics and are at a higher risk of mortality. The 
present study was undertaken to evaluate interac-
tions between hyperglycemia and clotting factors in 
COVID-19 patients. 
Methods. In this retrospective observational study, 
53 real-time RT-PCR SARS-CoV-2 positive cases in 40 to 
70 years of age, representing both sexes, were enrolled 
in the study from SMS Medical College, Jaipur (Ra-
jasthan, India). Based on their history of diabetes mel-
litus and exclusion criterion, patients were divided into 
diabetics (N = 11) and non-diabetics (N = 17) groups. 
The data on clinical profile and coagulation profile 
was recorded along with the markers of inflammation 
and infection. The two groups were compared using 
the Mann-Whitney test and the Fisher’s exact test. 
Correlation coefficients between clotting factors were 
compared between two groups using Student t test. 
Results. There was no significant difference in age 
(p = 0.25) or gender (p = 0.12) between the two groups. 
The coagulation indicators FDP (p = 0.79), D-dimer 
(p = 0.30), APPT (p = 0.96), PT (p = 0.79), INR (p = 1.00) 
PLT (p = 0.17) and the markers of inflammation and 
infection did not differ significantly between the two 
groups. There was no significant difference in cor-
relation coefficients among coagulation indicators 
between the two groups (p > 0.05). 
Conclusion. The study concludes that pathogenesis in 
clotting system is not significantly different in stud-
ied groups. Further research is needed to explain the 
higher mortality in diabetic patients suffering from 
COVID-19. (Clin Diabetol 2021; 10, 1: 114–122)
Key words: clotting factors, COVID-19, diabetes 
mellitus, hyperglycemia, SARS-CoV-2
Introduction
As of 21 November 2020, World Health Organiza-
tion reported 57,274,018 cases and 1,368,000 deaths 
due to severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) infection for all countries of the world 
[1]. In 2019, International Diabetes Federation, reported 
that 463 million adults suffer from diabetes mellitus 
[2]. Diabetes mellitus is an important risk factor that 
causes adverse outcome in COVID-19, similar to influ-
enza related mortality. Disease specific mortality rates 
due to diabetes outnumber mortality rate due to other 
cardiovascular diseases and cancer [3]. 
The molecular mechanisms that lead to diabetic 
complications have been studied extensively and in-
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volve reactive oxygen species (ROS) such as hydrogen 
peroxide and superoxide anions [4, 5]. These reactive 
species could deteriorate the cellular functions of 
multiple systems of the body. The pathophysiological 
mechanisms of COVID-19 has been explained. The 
angiotensin converting enzyme 2 (ACE-2) receptors 
are present in multiple organ systems of the body. The 
entry of SARS-CoV-2 via ACE-2 receptors in respiratory 
tract cells and pneumocytes has been mentioned. 
Further pathogenesis involve inflammatory response 
including recruitment of cells and a cytokine storm. 
In severe conditions, there is an activation of the co-
agulation cascade that can lead to thrombogenesis 
and disseminate intravascular coagulation resulting in 
death of the patient [6].
An area of prime importance is the common path-
way where pathogenesis of COVID-19 and diabetes 
mellitus interact. Furthermore, that common pathway 
might be an area we can intervene therapeutically in 
patients with diabetes mellitus who are suffering from 
COVID-19. The present study is undertaken to explore 
the effects on coagulation and the fibrinolytic system in 
diabetics and non-diabetics suffering from COVID-19.
Material and methods
A hospital based retrospective observational study 
was planned to compare indicators of coagulation, 
and markers of inflammation and infection between 
diabetics and non-diabetics in patients suffering from 
COVID-19. The study was approved by the institutional 
ethics committee. 
Participants 
We enrolled 53 patients. They all had SARS-CoV-2 
(identified with real-time RT-PCR) and were 40 to 70 
years of age, of either sex, obtained from SMS Medical 
College, Jaipur, Rajasthan, India. On the basis of his-
tory of diabetes mellitus, patients were divided into 
two groups: diabetics with COVID-19 (N = 20) and 
non-diabetics with COVID-19 (N = 33). As per our cri-
teria, patients with co-morbidities other than diabetes 
mellitus were excluded. After exclusion, the diabetic 
group had 11 patients and the non-diabetic group has 
17 patients (Figure 1).
Data collection
The age, gender and COVID-19 symptoms were 
recorded from case sheets. The coagulation indictors 
included fibrin degradation products (FDP) in mg per 
liter, D-dimer in mg per liter FEU, activated partial 
thromboplastin time (APTT) in seconds, prothrombin 
time (PT)in seconds, and the international normalized 
ratio (INR). The inflammatory mediators included eryth-
rocyte sedimentation rate (ESR) in mm for the 1st hour), 
ferritin (mg per liter) and procalcitonin (PCT) in mg per 
liter. Other hematologic indictors were recorded, includ-
ing hemoglobin (Hb) in gm%, total leukocyte count 
(TLC) in thousand cells per mm3, differential neutrophil 
(N = 53)
Subjects with following inclusion criterion:
 RT-PCR SARS-CoV-2 positive cases•





N=9 excluded due 
to comorbidity
N = 16 excluded due 
to comorbidity 







and hematological parameters 
between two groups
Statistical analysis and outcome
Figure 1. Flowchart of the study
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count (%), differential lymphocyte count (%), platelet 
count (PLT) in 105 per mm3 and C-reactive protein 
(CRP). Furthermore, differential neutrophil count to 
differential lymphocyte count ratio (NLR) and platelet 
count to differential lymphocyte count ratio (PLR) were 
calculated, and added to database.
Statistical analysis 
Due to the small sample size, non-parametric analysis 
was performed. The quantitative variables were expressed 
as median (1st Quartile, 3rd Quartile) and compared with 
the non-parametric Mann-Whitney’s test. Similarly, the 
qualitative attributes were expressed as proportions and 
compared with the two-tailed Fisher’s exact test. Pearson 
correlations among trait pairs were calculated. Pearson 
correlations were contrasted between the two groups 
using Student t test [7] The statistical significance level 
was considered at 5%. MS Excel 2010 was used to build 
the database and JASP (version 0.12.2) [8] and MATLAB 
(2016a) [9] was used for statistical analysis.
Results 
The median age of diabetics (median: 58, IQR: 10.5) 
and non-diabetics (median: 55, IQR: 17) did not found to 
differ significantly (p = 0.25). The gender between two 
groups did not differ significantly (p = 0.12) (Table 1, 
Figure 2). The diabetic group have one patient with type 
1 DM (9%) and remaining patients were with type 2 DM 
(91%). The median length of hospital stay was longer 
in diabetic group (14.5 days) then non-diabetic group 
(10 days). In diabetic group, 10 among 11 patients have 
been recovered (91%) while 1 was admitted (9%). In 
case of non-diabetic group, 14 cases has been recovered 
(82.4%), 1 was admitted (5.8%) and 2 died (11.8%).
The proportion of patients with the symptoms of 
fever and cough were significantly higher in the diabetic 
group (p = 0.02) . In contrast, the proportions of other 
symptoms such as shortness of breath (SOB) and sore 
throat did differ significantly between the two groups 
(p > 0.05) (Table 2, Figure 3). 
The coagulation profile showed no significant dif-
ference with FDP (p = 0.79), D-Dimer (p = 0.30), APTT 
(p = 0.96), PT (p = 0.79) or INR (p = 1.00) between 
diabetics and non-diabetics (Table 1, Figure 2).
The markers of inflammation showed no significant 
difference in ferritin (p = 0.22), ESR (p = 0.08 ) or PCT 
(p = 0.25 ) between diabetics and non-diabetics (Table 1 
and Figure 2). The CRP (p = 0.69) also did not differ 
significantly between the two groups (Table 2).
Similarly, the routine hematologic parameters 
showed no significant difference in Hb (p = 0.90), 
TLC (p = 0.83), NPHIL (p = 0.74), LYMP (p = 0.78), PLT 
(p = 0.17), NLR (p = 0.78) and PLR (p = 0.48) between 
diabetics and non-diabetics (Table 1, Figure 2).
The correlation coefficients among various co-
agulation indicators was calculated for diabetic and 
non-diabetic patients suffering from coronavirus 
disease-19. (Figures 4–6). The differences in Pearson’s 
correlation coefficient were not significant between 








FDP D-dimer APTT PT INR Hb TLC NPHIL LYMP NLR PLRPLT ESR Ferritin PCT
Figure 2. Comparison of medians of clinical and hematological parameters in diabetic and non-diabetic patients. Age (in × 101 
years); FDP — fibrin degradation products (mg per litre); D-dimer (mg per litre FEU; APTT — activated partial thromboplastin 
time (× 10 s); PT — prothrombin time (s); INR — international normalized ratio; Hb — hemoglobin (gm%); TLC — total leukocyte 
count (× 103 cells per cubic millimeter); neutrophil — differential neutrophil count (× 10 %); lympocyte — differential lymphocyte 
count (× 10 %); NLR — neutrophil lymphocyte ratio; PLT — platelet count (× 105 per cubic millimeter); PLR — platelet lymphocyte 
ratio (× 10-1); ESR — erythrocyte sedimentation rate (× 10 in 1st hour); ferritin (× 10 micrograms per liter ); PCT — procalcitonin 
(× 10-2 microgram per liter)





















Female Fever Cough SOB CRPSore throat
Figure 3. Comparison of proportions in clinical and hematological attributes in diabetic and non-diabetic patients. SOB — short-
ness of breath
Table 1. Clinical and hematological parameters in diabetic and non-diabetics patient (using non-parametric Mann Whitney test)
Variables Groups Median 1st Quartile 3rd Quartile P
Age Non-diabetics 55 44 61 0.25
Diabetics 58 52 62.5
FDP Non-diabetics 4 4 12.6 0.79
Diabetics 4 4 15.4
D-dimer Non-diabetics 0.6 0.2 2.6 0.30
Diabetics 0.5 0.5 3.7
APTT Non-diabetics 30.6 27.1 32.4 0.96
Diabetics 31.6 31.5 31.9
PT Non-diabetics 12.5 12 13.5 0.79
Diabetics 12.7 11.9 14.55
INR Non-diabetics 0.9 0.9 1 1.00
Diabetics 0.9 0.9 1.1
Hb Non-diabetics 13 13 13.5 0.90
Diabetics 13.6 12.5 13.9
TLC Non-diabetics 5.93 4.5 8.2 0.83
Diabetics 6.8 4.15 9.135
NPHIL Non-diabetics 68 56.5 73.3 0.74
Diabetics 63.5 60 70.55
LYMP Non-diabetics 22.9 20 35.4 0.78
Diabetics 32 21.35 32
NLR Non-diabetics 3.201 1.54 3.6 0.78
Diabetics 1.913 1.875 3.687
PLT Non-diabetics 1.58 1.4 2.13 0.17
Diabetics 2.17 1.605 2.725
PLR Non-diabetics 0.069 0.031 0.127 0.48
Diabetics 0.079 0.05 0.128
ESR Non-diabetics 22 15 44 0.08
Diabetics 40 25 64.5
Ferritin Non-diabetics 96 68 280 0.22
Diabetics 146 109.45 535
PCT Non-diabetics 0.02 0.02 0.04 0.25
Diabetics 0.05 0.02 0.072
FDP — fibrin degradation products; APTT — activated partial thromboplastin time; PT — prothrombin time; INR — international normalized ratio; Hb — 
hemoglobin; TLC — total leukocyte count; NPHIL — neutrophil; LYMP — lymphocyte; NLR — neutrophil lymphocyte ratio; PLT — platelet lymphocyte ratio; 
ESR — erythrocyte sedimentation rate; PCT — procalcitonin
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The relationship between APTT and PT shows iso-
lated increase of PT in both diabetics and non-diabetics 
(Figure 7). 
Discussion 
The present study is an effort to explore the effects 
on coagulation and the fibrinolysis cascade in diabetics 
and non-diabetics suffering from SARS-CoV-2 infection. 
As reported by Bloomgarden diabetes mellitus is an 
important risk factor of adverse outcome in COVID-19, 
as with other influenza related mortality [3]. Disease 
specific mortality rates due to diabetes outnumber 
risks due to other cardiovascular diseases and cancer. 
Blood is a complex fluid and consists of plasma and 
formed elements — the red blood cells (RBCs), white 
blood cells (WBCs) and platelets. The role of coagulation 
and the fibrinolytic system is to prevent the blood from 
leaking through the blood vessels and keep the blood 
in liquid state respectively. The coagulation cascade 
involves the surface-activated intrinsic pathway, the 
tissue factor-activated extrinsic pathway, and the com-
mon pathway. The controlling event is the generation 
of thrombin, that is highly controlled dynamic process. 
Thrombin itself has multiple roles, both positive and 
negative in its production as well as removal. The met-
rics signifying role of various coagulation pathways has 
been mentioned. An isolated increase in prothrombin 
time (PT) indicates FVII deficiency, whereas increased 
APTT suggests most commonly FVIII or FXI deficiency. 
The prolongation of both PT and APTT suggests defi-
ciency of FV, FX, FII, or fibrinogen abnormalities. The 
exposure of blood to phospholipids from damaged 
tissue, hemolysis, and endothelial damage lead to de-
velopment of disseminated intravascular coagulation 
(DIC). The main mechanism is the uncontrolled produc-
tion of thrombin by exposure of blood to pathologic 
levels of tissue factor. The most sensitive test for DIC is 
FDP level. The D-dimer test is more specific for detec-
tion of fibrin [10–12].
Our study showed that the coagulation and fi-
brinolysis system did not differ significantly in diabetic 
and non-diabetic patients suffering from COVID-19 
(Figure 3, 4). In addition, the markers of inflammation, 
including ferritin, ESR, procalcitonin and CRP did not 
differ significantly. The proportions of patients suffering 
Table 2. Clinical and hematological attributes in diabetic 




Diabetics Odds  
ratio (OR)
P
Female 52.941 18.182 5.06 0.12
Fever 23.529 72.727 8.67 0.02
Cough 23.529 72.727 8.67 0.02
SOB 11.765 27.273 2.81 0.35
Sore Throat 5.882 9.091 1.60 1.00
CRP 58.824 72.727 1.87 0.69 
SOB — shortness of breath
Table 3. Comparison of Pearson’s correlation coefficients among coagulation indicators between diabetics and 
non-diabetics suffering from COVID-19
Variable 1 Variable 2 Pearson’s correlation coefficient  
(diabetics)
Pearson’s correlation coefficient  
(non-diabetics)
Z P
FDP D-dimer 0.999 0.93 2.10 < 0.05
FDP APTT 0.207 0.135 0.07 > 0.05
FDP PT 0.695 0.008 0.83 > 0.05
FDP INR 0.761 0.613 0.28 > 0.05
FDP PLT -0.333 -0.077 -0.26 > 0.05
D-dimer APTT 0.21 0.198 0.01 > 0.05
D-dimer PT 0.694 0.1 0.74 > 0.05
D-dimer INR 0.757 0.68 0.16 > 0.05
D-dimer PLT -0.321 -0.038 -0.29 > 0.05
APTT PT -0.507 -0.305 -0.24 > 0.05
APTT INR -0.463 0.001 -0.49 > 0.05
APTT PLT 0.05 -0.301 0.35 > 0.05
PT INR 0.953 0.603 1.14 > 0.05
PT PLT -0.114 0.254 -0.37 > 0.05
FDP — fibrin degradation products; APTT — activated partial thromboplastin time; PT — prothrombin time; INR — international normalized ratio; PLT — 
platelet lymphocyte ratio




























































































Figure 4. Correlation matrix heat maps among coagulation parameters. The color range from light to dark represents positive 
to negative correlation, respectively. APTT — activated partial thromboplastin time; FDP — fibrin degradation products; INR — 
international normalized ratio; PT — prothrombin time
Figure 5. Correlation matrix showing correlation between coagulation indicators in non-diabetics suffering from COVID-19. 
APTT — activated partial thromboplastin time; FDP — fibrin degradation products; INR — international normalized ratio; PT — 
prothrombin time
Figure 6. Correlation matrix showing correlation between coagulation indicators in diabetics suffering from COVID-19. APTT 
— activated partial thromboplastin time; FDP — fibrin degradation products; INR — international normalized ratio; PT — pro-
thrombin time
Clinical Diabetology 2021, Vol. 10, No. 1
120
from fever and cough are higher in diabetics as com-
pared to non-diabetics. The correlation between APPT 
and PT showed isolated increase in PT, suggesting role 
of tissue factor pathway. The difference in correlations 
among FDP, D-dimer, APPT, PT and INR between diabetics 
and non-diabetics did not differ significantly. In addition, 
the differential neutrophil counts and lymphocyte counts 
are not differ significantly in the two groups.
The pathogenesis of COVID-19 involves entry of 
SARS-CoV-2 into respiratory tract cells via angiotensin 
converting enzyme 2 receptors. Singh mentioned ACE-2 
receptors expressed not only in the type I and II alveolar 
epithelial cells in the lungs and upper respiratory tract, but 
in heart, endothelium, renal tubular epithelium, intestinal 
epithelium, and pancreas. The binding of S-glycoprotein 
on the surface of SARS-CoV-2 with ACE-2 causes a con-
formational change in the S-glycoprotein. That lead to 
proteolytic digestion by host cell proteases (TMPRSS2 
and furin) and internalization of the viral particles. The 
human cell synthesizes IFN-a and IFN-b in response to 
viral infection . The IFN responses are induced when 
double stranded RNA are sensed by binding proteins. 
The IFN act against the infected cell and limit viral repli-
cation. The inflammatory response was triggered by the 
entry of virus into the cell with recruitment of T helper 
cells which produce IFN-g Jose described the interplay 
between inflammation and coagulation in COVID-19. 
The overproduction of proinflammatory cytokines (tumor 
necrosis factor (TNF), IL-6, IL-1b called a cytokine storm, 
leading to vascular hyperpermeability. There is a crosstalk 
between coagulation and inflammation pathways. The 
thrombin promote clot formation by activating platelets 
and converting fibrinogen to fibrin. The thrombin aug-
ments inflammation via proteinase activated receptors 
(PAR). The formation of thrombin is controlled by negative 
feedback loops and anticoagulants, such as antithrom-
bin III, tissue factor pathway inhibitor, and the protein C 
system. The impairment of all the three control mecha-
nisms cause procoagulant-anticoagulant imbalance, that 
predisposes to microthrombosis, DIC, multi-organ failure 
and death [13].
The pulmonary pathology consists of hyaline 
membrane formation, desquamation of pneumocytes 
in alveolar spaces, and an presence of lymphocytes 
and monocytes in interstitial space. Giant cells can 
be seen and Type II pneumocytes showed presence 
of viral particles. [6,11].In a meta-analysis Aziz found 
IL-6 is an important proinflammatory biomarker for 
prediction of severe COVID-19 cases [14]. In a review, 
Terpos suggested prognostic value of NLR and peak PLR 
in determining severe cases [15]. Longitudinal evalua-
tion of lymphocyte count and markers of inflammation 
like LDH, CRP and IL-6 help in identification of cases 
with dismal prognosis. Biomarker, such as high serum 
procalcitonin and ferritin emerged as poor prognostic 
factors. Furthermore, hypercoagulability is correlated 
with adverse outcome. The elevated D-dimer levels, 
PT and APTT prolongation, increased FDP and severe 
thrombocytopenia lead to increased DIC [15, 16]. The 
autopsy findings of COVID-19 patients were assessed 
by Dolhnikoff and confirmed the presence of pulmo-
nary thrombosis. They found endothelial tumefaction 
and pulmonary megakaryocytes in the pulmonary 
capillaries that might be responsible for activation of 
the coagulation cascade [17]. In a similar study Con-
nors demonstrated presence of multinucleated cells 




































Figure 7. The correlation coefficient between prothrombin time and activated partial thromboplastin time in diabetic and non-
diabetic patients
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The molecular mechanism of diabetic complica-
tions involve increased mitochondrial reactive oxygen 
species (ROS) due to high glucose levels. The normaliza-
tion of production of ROS by mitochondrial metabolic 
inhibitors and overexpression of uncoupling protein-1 
(UCP-1) or manganese superoxide dismutase (MnSOD), 
prevents glucose-induced activation of protein kinase 
C (PKC), formation of advanced glycation end products 
(AGEs), and accumulation of sorbitol, all of which 
lead to diabetic complications [4]. Ceriello reviewed 
the hypothesis that hyperglycemia is the key factor 
in hypercoagulability in diabetics. Hyperglycemia acts 
through three molecular mechanisms that involve non-
enzymatic glycation, the development of increased 
oxidative stress and a decrease in the levels of hep-
aran sulphate. Hyperglycemia cause increased levels 
of FI, FVII, FVIII, von Willebrand Factor and FX [19]. 
In a review, Alzahrani reported that the expression of 
tissue factor by vascular and non-vascular cells was 
up-regulated due to presence of low grade inflamma-
tion in type 2 diabetes mellitus [20]. Increased levels 
of FVII were also evident, which increases the risk of 
thrombus formation. As reported by others, we found 
increased levels of FVII and tissue factor as evidenced 
by isolated increase in PT.
In a study with similar findings, Abdulla compared 
PT and APPT in diabetics and non-diabetics and found 
no significant difference between these two groups 
[21]. Bukhari studied effects of SARS-CoV-2 on gesta-
tional diabetes mellitus. Despite lack of placental infec-
tion by SARS-CoV-2, abnormal placental morphology 
has been recorded. Till now, no scientific proof has 
been documented regarding impact of COVID-19 on 
pregnancy and fetus [22].
The pathophysiological interactions in COVID-19 
and diabetes mellitus has been presented by Singh 
[6]. Several mechanisms has been emphasized other 
than the usual mechanism of impaired neutrophil 
chemotaxis and phagocytosis in diabetics, responsible 
for a higher mortality risk and severity of infection. The 
expression of ACE-2 receptors were found to be higher 
in the renal cortex, liver and pancreas, but not in the 
lungs. The significance of these observations is not clear 
at present, indicating ACE-2 expression may predispose 
diabetics to infection. Furthermore, increased furin, im-
paired T-Cell function, and increased interleukin-6 (IL-6) 
are seen in diabetics. As ACE-2 receptors are expressed 
in pancreatic islets, hyperglycemia has been observed 
in cases of SARS-CoV-2 without pre-existing diabetes. 
Conclusions
The study concludes that coagulation and fi-
brinolysis system is not the place of interactions in the 
pathogenesis of diabetes mellitus and SARS-CoV-2 
infection. Though the patients’ age is matched in our 
study, the age related changes may be one of the factor 
leading to higher mortality. Further explanatory studies 
are needed to explain the higher mortality in diabetic 
patients suffering from COVID-19. 
limitations of study
This is an hospital based study. The study has 
small sample size, therefore non-parametric analysis 
was performed. 
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